Skip to main content

Malignant Ascites

2
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Neovii Biotech
Neovii BiotechGermany - Grafelfing
1 program
1
catumaxomabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00326885Completed32Est. Aug 2010
Clover Biopharmaceuticals
Clover BiopharmaceuticalsChina - Changxing
1 program
1
SCB-313Phase 11 trial
Active Trials
NCT04051112Completed13Est. Apr 2022
Sequana Medical
Sequana MedicalGermany - Munich
2 programs
AlfapumpN/A1 trial
alfapump systemN/A1 trial
Active Trials
NCT03200106Completed17Est. Mar 2018
NCT04076566Withdrawn0Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Neovii Biotechcatumaxomab
Clover BiopharmaceuticalsSCB-313
Sequana Medicalalfapump system
Sequana MedicalAlfapump

Clinical Trials (4)

Total enrollment: 62 patients across 4 trials

NCT00326885Neovii Biotechcatumaxomab

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Start: Jun 2006Est. completion: Aug 201032 patients
Phase 2Completed
NCT04051112Clover BiopharmaceuticalsSCB-313

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

Start: Sep 2019Est. completion: Apr 202213 patients
Phase 1Completed
NCT04076566Sequana Medicalalfapump system

Malignant Ascites Alfapump® Study

Start: May 2020Est. completion: Mar 20220
N/AWithdrawn
NCT03200106Sequana MedicalAlfapump

Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites

Start: Aug 2017Est. completion: Mar 201817 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.